Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | THPO | P40225 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | GMNN | O75496 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.33 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2961918 | 0.85 | — | — | |
| SCHEMBL31315954 | 0.85 | — | — | |
| SCHEMBL2961922 | 0.85 | — | — | |
| Hydrochloric Acid SCHEMBL2887462 | 0.83 | HRH3 (0.45) | HRH3GNAI3GNAO1GNAI1 | |
| Hydrochloric Acid SCHEMBL25364459 | 0.83 | HRH3 (0.36) | HRH3TP53CYP1A2CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL25365794 | 0.83 | HRH3 (0.36) | HRH3TP53CYP1A2CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL25364464 | 0.83 | HRH3 (0.36) | HRH3TP53CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL2324241 | 0.77 | CARM1 (0.56) | HRH3ALDH1A1CARM1PRMT6PRMT1 | |
| SCHEMBL14351240 | 0.77 | GNAI3 (0.35) | TP53CYP1A2CYP3A4CYP2D6PKM | |
| SCHEMBL2956038 | 0.77 | KCNA3 (0.44) | HRH3TP53CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115835909-B | Cannabinoid receptor type 2 (CB 2) modulators and uses thereof | 泰昂治疗公司 | 2026-05-15 | — | — | CN | disclosed |
| US-20240252504-A1 | CANNABINOID RECEPTOR TYPE 2 (CB2) MODULATORS AND USES THEREOF | TEON THERAPEUTICS INC (US) | 2024-08-01 | — | — | US | disclosed |
| US-11957689-B2 | Cannabinoid receptor type 2 (CB2) modulators and uses thereof | TEON THERAPEUTICS, INC. (US) | 2024-04-16 | — | — | US | disclosed |
| US-20230143502-A1 | CANNABINOID RECEPTOR TYPE 2 (CB2) MODULATORS AND USES THEREOF | TEON THERAPEUTICS, INC | 2023-05-11 | — | — | US | disclosed |
| US-20230143502-A1 | CANNABINOID RECEPTOR TYPE 2 (CB2) MODULATORS AND USES THEREOF | TEON THERAPEUTICS, INC | 2023-05-11 | — | — | US | disclosed |
| US-20230143502-A1 | CANNABINOID RECEPTOR TYPE 2 (CB2) MODULATORS AND USES THEREOF | TEON THERAPEUTICS, INC | 2023-05-11 | — | — | US | disclosed |
| CN-115835909-A | Cannabinoid receptor type 2 (CB 2) modulators and uses thereof | 泰昂治疗公司 | 2023-03-21 | — | — | CN | disclosed |
| EP-4146345-A2 | CANNABINOID RECEPTOR TYPE 2 (CB2) MODULATORS AND USES THEREOF | Teon Therapeutics, Inc. (US) | 2023-03-15 | — | — | EP | disclosed |
| US-11564928-B1 | Cannabinoid receptor type 2 (CB2) modulators and uses thereof | TEON THERAPEUTICS, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| US-11564928-B1 | Cannabinoid receptor type 2 (CB2) modulators and uses thereof | TEON THERAPEUTICS, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| WO-2021226206-A2 | CANNABINOID RECEPTOR TYPE 2 (CB2) MODULATORS AND USES THEREOF | TEON THERAPEUTICS, INC. (US) | 2021-11-11 | — | — | WO | disclosed |
| US-9139589-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-9090601-B2 | Thiazole derivatives | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| EP-2391619-A1 | HETEROARYLS AND THEIR USE AS PI3K INHIBITORS | Millennium Pharmaceuticals, Inc. (US) | 2011-12-07 | — | — | EP | disclosed |
| US-20110003807-A1 | Thiazole derivatives | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| US-20110003806-A1 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| WO-2010090716-A1 | HETEROARYLS AND THEIR USE AS PI3K INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230143502-A1 | CANNABINOID RECEPTOR TYPE 2 (CB2) MODULATORS AND USES THEREOF | CNR2, CNR1, GPR18 | HRH3 332/4885TP53 4814/4885CYP1A2 1483/4885 |
| US-11564928-B1 | Cannabinoid receptor type 2 (CB2) modulators and uses thereof | CNR2, CNR1, GPR18 | HRH3 332/4885TP53 4814/4885CYP1A2 1483/4885 |
| US-20110003807-A1 | Thiazole derivatives | MTOR, RICTOR, AKT2 | HRH3 4615/4885TP53 713/4885CYP1A2 1643/4885 |
| US-20110003806-A1 | Heteroaryls and uses thereof | RICTOR, MTOR, AKT1S1 | HRH3 154/4885TP53 1415/4885CYP1A2 224/4885 |
| US-20240252504-A1 | CANNABINOID RECEPTOR TYPE 2 (CB2) MODULATORS AND USES THEREOF | CNR2, CNR1, GPR18 | HRH3 332/4885TP53 4814/4885CYP1A2 1483/4885 |
| US-11957689-B2 | Cannabinoid receptor type 2 (CB2) modulators and uses thereof | CNR2, CNR1, GPR18 | HRH3 332/4885TP53 4814/4885CYP1A2 1483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.